An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Graphite Bio Announces Participation in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Graphite Bio (NASDAQ: GRPH), a pioneering clinical-stage gene editing company, announced its management team will participate in three upcoming investor conferences. These include the BofA Securities Healthcare Conference on May 11, 2022, the RBC Capital Markets Global Healthcare Conference on May 18, 2022, and the UBS Global Healthcare Conference on May 23, 2022. The chats will be webcast live on Graphite Bio’s website, with replays available post-event. Graphite Bio focuses on high-efficiency precision gene repair for developing therapies to address serious diseases.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will participate in fireside chats at the following investor conferences:
BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 5:40 p.m. ET;
2022 RBC Capital Markets Global Healthcare Conference on Wednesday, May 18, 2022, at 11:30 a.m. ET; and
UBS Global Healthcare Conference 2022 on Monday, May 23, 2022, at 10 a.m. ET.
The fireside chats will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webcasts will be archived and available following the events.
About Graphite Bio Graphite Bio is a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications to transform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s UltraHDR™ gene editing platform is designed to precisely correct genetic mutations, replace entire disease-causing genes with functional genes or insert new genes into predetermined, safe locations. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, M.D., and Matthew Porteus, M.D., Ph.D.
What investor conferences will Graphite Bio participate in May 2022?
Graphite Bio will participate in the BofA Securities Healthcare Conference on May 11, 2022, the RBC Capital Markets Global Healthcare Conference on May 18, 2022, and the UBS Global Healthcare Conference on May 23, 2022.
What time will Graphite Bio's fireside chat occur at the BofA Securities Healthcare Conference?
The fireside chat at the BofA Securities Healthcare Conference will take place at 5:40 p.m. ET on May 11, 2022.
Where can I watch Graphite Bio's investor conference webcasts?
The webcasts of Graphite Bio's investor conferences can be watched live on their website at www.graphitebio.com.
What is Graphite Bio's focus in gene editing?
Graphite Bio focuses on high-efficiency precision gene repair to develop therapies for serious diseases.
